Short course treatment for P. vivax malaria in Papua New Guinea
Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria
This study is testing a shorter treatment for P. vivax malaria to see if it works well and is safe for people in Papua New Guinea, especially those with a specific health condition called G6PD deficiency.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 5850 (estimated) |
| Ages | 12 Months and up |
| Sex | All |
| Sponsor | Macfarlane Burnet Institute for Medical Research and Public Health Ltd Academic / other |
| Locations | 4 sites (Kokopo, East New Britain and 3 other locations) |
| Trial ID | NCT05874271 on ClinicalTrials.gov |
What this trial studies
This study evaluates a revised case management package for treating P. vivax malaria, focusing on the feasibility and cost-effectiveness of a short course of primaquine. Given the challenges of treating P. vivax due to its dormant liver stages and the risks associated with G6PD deficiency, the study aims to improve treatment adherence and outcomes. It targets patients with vivax malaria while considering the safety of those with G6PD deficiency. The study is conducted in collaboration with local health authorities and medical research institutions in Papua New Guinea.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with vivax malaria.
Not a fit: Patients who are pregnant, breastfeeding, or have severe malaria will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the treatment and management of P. vivax malaria, leading to better patient outcomes.
How similar studies have performed: Other studies have shown promise in improving malaria treatment adherence and outcomes, but this specific approach is innovative and tailored to the unique challenges of P. vivax.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with vivax malaria Exclusion Criteria: * Patients who are pregnant * Patients who are breastfeeding * Patients with a Hb \<8g/dL * Patients with a previous adverse reaction to primaquine * Patient with severe malaria
Where this trial is running
Kokopo, East New Britain and 3 other locations
- Napapar Health Centre — Kokopo, East New Britain, Papua New Guinea (Recruiting)
- Wirui Clinic — Wewak, East Sepik, Papua New Guinea (Recruiting)
- Baro Clinic — Vanimo, West Sepik, Papua New Guinea (Recruiting)
- Mugil Health Centre — Madang, Papua New Guinea (Recruiting)
Study contacts
- Principal investigator: Moses Laman, Dr — Papua New Guinea Institute of Medical Research
- Study coordinator: Evelien Rosens, MSc
- Email: evelien.rosens@burnet.edu.au
- Phone: +61 3 9282 2111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.